AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. OBIO
  4. [Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity

[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Orchestra BioMed Holdings (OBIO) reported insider trading activity through a Form 4 filing for Director David Pacitti. On June 24, 2025, Pacitti received two equity compensation awards:

  • 12,422 Restricted Stock Units (RSUs) with a $0 exercise price, bringing his direct ownership to 29,968 shares
  • 36,797 Stock Options with an exercise price of $3.22 per share, expiring June 24, 2035

Both the RSUs and stock options will vest in a single installment at the earlier of: (1) one-year anniversary of the grant date, or (2) the company's 2026 Annual Meeting of Stockholders, subject to continued service. This equity compensation aligns the director's interests with shareholders through a combination of full-value shares and performance incentives.

Orchestra BioMed Holdings (OBIO) ha comunicato un'attivit脿 di insider trading tramite una dichiarazione Form 4 per il Direttore David Pacitti. Il 24 giugno 2025, Pacitti ha ricevuto due premi di compensazione azionaria:

  • 12.422 Unit脿 Azionarie Vincolate (RSU) con prezzo di esercizio pari a $0, portando la sua propriet脿 diretta a 29.968 azioni
  • 36.797 Opzioni Su Azioni con prezzo di esercizio di $3,22 per azione, in scadenza il 24 giugno 2035

Sia le RSU che le opzioni azionarie matureranno in un'unica tranche al verificarsi del primo tra: (1) il primo anniversario della data di assegnazione, o (2) l鈥橝ssemblea Annuale degli Azionisti 2026 della societ脿, subordinatamente al mantenimento del rapporto di lavoro. Questa forma di compensazione azionaria allinea gli interessi del direttore con quelli degli azionisti attraverso una combinazione di azioni a valore pieno e incentivi legati alle performance.

Orchestra BioMed Holdings (OBIO) report贸 actividad de operaciones internas mediante una presentaci贸n del Formulario 4 para el Director David Pacitti. El 24 de junio de 2025, Pacitti recibi贸 dos premios de compensaci贸n en acciones:

  • 12,422 Unidades de Acciones Restringidas (RSUs) con un precio de ejercicio de $0, aumentando su propiedad directa a 29,968 acciones
  • 36,797 Opciones sobre Acciones con un precio de ejercicio de $3.22 por acci贸n, que expiran el 24 de junio de 2035

Tanto las RSUs como las opciones sobre acciones se consolidar谩n en un solo pago en la fecha que ocurra primero entre: (1) el primer aniversario de la fecha de concesi贸n, o (2) la Junta Anual de Accionistas 2026 de la compa帽铆a, sujeto a la continuidad del servicio. Esta compensaci贸n en acciones alinea los intereses del director con los de los accionistas mediante una combinaci贸n de acciones de valor completo e incentivos por desempe帽o.

Orchestra BioMed Holdings (OBIO)電� 鞚挫偓 David Pacitti鞐� 雽�頃� 雮措秬鞛� 瓯半灅 頇滊彊鞚� Form 4 鞝滌稖鞚� 韱淀暣 氤搓碃頄堨姷雼堧嫟. 2025雲� 6鞗� 24鞚�, Pacitti電� 霊� 臧�歆� 欤检嫕 氤挫儊 靾橃棳毳� 氚涭晿鞀惦媹雼�:

  • 12,422 鞝滍暅 欤检嫕 雼渼(RSU)搿� 頄夓偓臧�瓴╈潃 $0鞚措┌, 攴胳潣 歆侅爲 靻岇湢 欤检嫕鞚� 29,968欤缄皜 霅橃棃鞀惦媹雼�
  • 36,797 欤检嫕 鞓奠厴鞙茧 欤茧嫻 頄夓偓臧�瓴╈潃 $3.22鞚措┌, 毵岆鞚检潃 2035雲� 6鞗� 24鞚检瀰雼堧嫟

RSU鞕� 欤检嫕 鞓奠厴 氇憪 雼れ潓 欷� 牍犽ジ 鞁滌爯鞐� 雼澕 頃犽秬搿� 氩犾姢韺呺惄雼堧嫟: (1) 靾橃棳鞚茧攵�韯� 1雲� 旮半厫鞚�, 霕愲姅 (2) 須岇偓鞚� 2026雲� 鞐半 欤检＜齑濏殞, 歆�靻嶌爜鞚� 攴茧 臁瓣贝 頃橃棎. 鞚� 欤检嫕 氤挫儊鞚� 鞝勳暋 臧�旃� 欤检嫕瓿� 靹标臣 鞚胳劶韹半笇毳� 瓴绊暕頃橃棳 鞚挫偓鞚� 鞚错暣甏�瓿勲ゼ 欤检＜鞕� 鞚检箻鞁滍偟雼堧嫟.

Orchestra BioMed Holdings (OBIO) a d茅clar茅 une activit茅 d鈥檌niti茅s via un d茅p么t de formulaire 4 concernant le Directeur David Pacitti. Le 24 juin 2025, Pacitti a re莽u deux attributions de r茅mun茅ration en actions :

  • 12 422 unit茅s d鈥檃ctions restreintes (RSU) avec un prix d鈥檈xercice de 0 $, portant sa d茅tention directe 脿 29 968 actions
  • 36 797 options d鈥檃chat d鈥檃ctions avec un prix d鈥檈xercice de 3,22 $ par action, expirant le 24 juin 2035

Les RSU et les options d鈥檃chat d鈥檃ctions seront acquises en une seule fois au premier des deux 茅v茅nements suivants : (1) l鈥檃nniversaire d鈥檜n an de la date d鈥檃ttribution, ou (2) l鈥檃ssembl茅e g茅n茅rale annuelle des actionnaires 2026, sous r茅serve de la poursuite du service. Cette r茅mun茅ration en actions aligne les int茅r锚ts du directeur avec ceux des actionnaires gr芒ce 脿 une combinaison d鈥檃ctions 脿 pleine valeur et d鈥檌ncitations 脿 la performance.

Orchestra BioMed Holdings (OBIO) meldete Insiderhandelst盲tigkeiten durch eine Form 4 Einreichung f眉r Direktor David Pacitti. Am 24. Juni 2025 erhielt Pacitti zwei Aktienverg眉tungszuteilungen:

  • 12.422 Restricted Stock Units (RSUs) mit einem Aus眉bungspreis von 0 $, wodurch sein Direktbesitz auf 29.968 Aktien anstieg
  • 36.797 Aktienoptionen mit einem Aus眉bungspreis von 3,22 $ pro Aktie, g眉ltig bis zum 24. Juni 2035

Sowohl die RSUs als auch die Aktienoptionen werden in einer einzigen Tranche f盲llig, und zwar zu dem fr眉heren Zeitpunkt von: (1) dem einj盲hrigen Jubil盲um des Gew盲hrungsdatums oder (2) der Hauptversammlung 2026 des Unternehmens, vorbehaltlich fortgesetzter Dienstzeit. Diese Aktienverg眉tung richtet die Interessen des Direktors durch eine Kombination aus vollwertigen Aktien und leistungsabh盲ngigen Anreizen mit denen der Aktion盲re aus.

Positive
  • None.
Negative
  • None.

Orchestra BioMed Holdings (OBIO) ha comunicato un'attivit脿 di insider trading tramite una dichiarazione Form 4 per il Direttore David Pacitti. Il 24 giugno 2025, Pacitti ha ricevuto due premi di compensazione azionaria:

  • 12.422 Unit脿 Azionarie Vincolate (RSU) con prezzo di esercizio pari a $0, portando la sua propriet脿 diretta a 29.968 azioni
  • 36.797 Opzioni Su Azioni con prezzo di esercizio di $3,22 per azione, in scadenza il 24 giugno 2035

Sia le RSU che le opzioni azionarie matureranno in un'unica tranche al verificarsi del primo tra: (1) il primo anniversario della data di assegnazione, o (2) l鈥橝ssemblea Annuale degli Azionisti 2026 della societ脿, subordinatamente al mantenimento del rapporto di lavoro. Questa forma di compensazione azionaria allinea gli interessi del direttore con quelli degli azionisti attraverso una combinazione di azioni a valore pieno e incentivi legati alle performance.

Orchestra BioMed Holdings (OBIO) report贸 actividad de operaciones internas mediante una presentaci贸n del Formulario 4 para el Director David Pacitti. El 24 de junio de 2025, Pacitti recibi贸 dos premios de compensaci贸n en acciones:

  • 12,422 Unidades de Acciones Restringidas (RSUs) con un precio de ejercicio de $0, aumentando su propiedad directa a 29,968 acciones
  • 36,797 Opciones sobre Acciones con un precio de ejercicio de $3.22 por acci贸n, que expiran el 24 de junio de 2035

Tanto las RSUs como las opciones sobre acciones se consolidar谩n en un solo pago en la fecha que ocurra primero entre: (1) el primer aniversario de la fecha de concesi贸n, o (2) la Junta Anual de Accionistas 2026 de la compa帽铆a, sujeto a la continuidad del servicio. Esta compensaci贸n en acciones alinea los intereses del director con los de los accionistas mediante una combinaci贸n de acciones de valor completo e incentivos por desempe帽o.

Orchestra BioMed Holdings (OBIO)電� 鞚挫偓 David Pacitti鞐� 雽�頃� 雮措秬鞛� 瓯半灅 頇滊彊鞚� Form 4 鞝滌稖鞚� 韱淀暣 氤搓碃頄堨姷雼堧嫟. 2025雲� 6鞗� 24鞚�, Pacitti電� 霊� 臧�歆� 欤检嫕 氤挫儊 靾橃棳毳� 氚涭晿鞀惦媹雼�:

  • 12,422 鞝滍暅 欤检嫕 雼渼(RSU)搿� 頄夓偓臧�瓴╈潃 $0鞚措┌, 攴胳潣 歆侅爲 靻岇湢 欤检嫕鞚� 29,968欤缄皜 霅橃棃鞀惦媹雼�
  • 36,797 欤检嫕 鞓奠厴鞙茧 欤茧嫻 頄夓偓臧�瓴╈潃 $3.22鞚措┌, 毵岆鞚检潃 2035雲� 6鞗� 24鞚检瀰雼堧嫟

RSU鞕� 欤检嫕 鞓奠厴 氇憪 雼れ潓 欷� 牍犽ジ 鞁滌爯鞐� 雼澕 頃犽秬搿� 氩犾姢韺呺惄雼堧嫟: (1) 靾橃棳鞚茧攵�韯� 1雲� 旮半厫鞚�, 霕愲姅 (2) 須岇偓鞚� 2026雲� 鞐半 欤检＜齑濏殞, 歆�靻嶌爜鞚� 攴茧 臁瓣贝 頃橃棎. 鞚� 欤检嫕 氤挫儊鞚� 鞝勳暋 臧�旃� 欤检嫕瓿� 靹标臣 鞚胳劶韹半笇毳� 瓴绊暕頃橃棳 鞚挫偓鞚� 鞚错暣甏�瓿勲ゼ 欤检＜鞕� 鞚检箻鞁滍偟雼堧嫟.

Orchestra BioMed Holdings (OBIO) a d茅clar茅 une activit茅 d鈥檌niti茅s via un d茅p么t de formulaire 4 concernant le Directeur David Pacitti. Le 24 juin 2025, Pacitti a re莽u deux attributions de r茅mun茅ration en actions :

  • 12 422 unit茅s d鈥檃ctions restreintes (RSU) avec un prix d鈥檈xercice de 0 $, portant sa d茅tention directe 脿 29 968 actions
  • 36 797 options d鈥檃chat d鈥檃ctions avec un prix d鈥檈xercice de 3,22 $ par action, expirant le 24 juin 2035

Les RSU et les options d鈥檃chat d鈥檃ctions seront acquises en une seule fois au premier des deux 茅v茅nements suivants : (1) l鈥檃nniversaire d鈥檜n an de la date d鈥檃ttribution, ou (2) l鈥檃ssembl茅e g茅n茅rale annuelle des actionnaires 2026, sous r茅serve de la poursuite du service. Cette r茅mun茅ration en actions aligne les int茅r锚ts du directeur avec ceux des actionnaires gr芒ce 脿 une combinaison d鈥檃ctions 脿 pleine valeur et d鈥檌ncitations 脿 la performance.

Orchestra BioMed Holdings (OBIO) meldete Insiderhandelst盲tigkeiten durch eine Form 4 Einreichung f眉r Direktor David Pacitti. Am 24. Juni 2025 erhielt Pacitti zwei Aktienverg眉tungszuteilungen:

  • 12.422 Restricted Stock Units (RSUs) mit einem Aus眉bungspreis von 0 $, wodurch sein Direktbesitz auf 29.968 Aktien anstieg
  • 36.797 Aktienoptionen mit einem Aus眉bungspreis von 3,22 $ pro Aktie, g眉ltig bis zum 24. Juni 2035

Sowohl die RSUs als auch die Aktienoptionen werden in einer einzigen Tranche f盲llig, und zwar zu dem fr眉heren Zeitpunkt von: (1) dem einj盲hrigen Jubil盲um des Gew盲hrungsdatums oder (2) der Hauptversammlung 2026 des Unternehmens, vorbehaltlich fortgesetzter Dienstzeit. Diese Aktienverg眉tung richtet die Interessen des Direktors durch eine Kombination aus vollwertigen Aktien und leistungsabh盲ngigen Anreizen mit denen der Aktion盲re aus.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pacitti David
(Last) (First) (Middle)
C/O ORCHESTRA BIOMED HOLDINGS, INC.
150 UNION SQUARE DRIVE
(Street)
NEW HOPE PA 18938
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.0001 per share ("Common Stock") 06/24/2025 A 12,422(1) A $0 29,968 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $3.22 06/24/2025 A 36,797 (2) 06/24/2035 Common Stock 36,797 $0 36,797 D
Explanation of Responses:
1. Represents an award of restricted stock units ("RSUs") awarded to the Reporting Person on June 24, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will vest in one installment on the earlier of (x) the one year anniversary of the Grant Date or (y) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such dates.
2. The stock options will vest in one installment on the earlier of (x) the one year anniversary of the Grant Date or (y) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such dates.
/s/ Andrew Taylor, Attorney-in-Fact 06/26/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What stock grants did OBIO director David Pacitti receive on June 24, 2025?

David Pacitti received two equity grants on June 24, 2025: (1) 12,422 restricted stock units (RSUs) and (2) stock options to purchase 36,797 shares of common stock at an exercise price of $3.22 per share.

When do David Pacitti's OBIO RSUs and stock options vest?

Both the RSUs and stock options will vest in one installment on the earlier of: (1) the one-year anniversary of the grant date (June 24, 2026) or (2) the date of OBIO's 2026 Annual Meeting of Stockholders, subject to continuous service.

How many shares of OBIO stock does David Pacitti own after the June 2025 grants?

Following the transactions, David Pacitti directly owns 29,968 shares of OBIO common stock and 36,797 stock options. The 12,422 RSUs will convert to common shares upon vesting.

What is the exercise price and expiration date of OBIO stock options granted to Pacitti?

The stock options were granted with an exercise price of $3.22 per share and expire on June 24, 2035, ten years from the grant date.
Stock OBIO logo
Orchestra BioMed Holdings Inc

NASDAQ:OBIO

OBIO Rankings

#4473 Ranked by Market Cap
N/A Ranked by Dividends

OBIO Latest News

Aug 26, 2025
Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology
Aug 14, 2025
Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction
Aug 12, 2025
Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
Aug 8, 2025
Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility
Aug 5, 2025
Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings

OBIO Latest SEC Filings

Aug 25, 2025
[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity
Aug 25, 2025
[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity
Aug 25, 2025
[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity
Aug 25, 2025
[Form 4] Orchestra BioMed Holdings, Inc. Insider Trading Activity
Aug 12, 2025
[10-Q] Orchestra BioMed Holdings, Inc. Quarterly Earnings Report

OBIO Stock Data

140.28M
39.91M
16.19%
34.98%
1.31%
Biotechnology
Surgical & Medical Instruments & Apparatus
United States
NEW HOPE